164 related articles for article (PubMed ID: 15454688)
21. Laboratory animal science issues in the design and conduct of studies with endocrine-active compounds.
Everitt JI; Foster PM
ILAR J; 2004; 45(4):417-24. PubMed ID: 15454680
[TBL] [Abstract][Full Text] [Related]
22. Animal models and studies of in utero endocrine disruptor effects.
Vandenbergh JG
ILAR J; 2004; 45(4):438-42. PubMed ID: 15454682
[TBL] [Abstract][Full Text] [Related]
23. Endocrine disruption comes into regulatory focus.
Baltz D
New Solut; 1999; 9(1):29-35. PubMed ID: 17208914
[TBL] [Abstract][Full Text] [Related]
24. Perils of paradigm: complexity, policy design, and the Endocrine Disruptor Screening Program.
Vogel JM
Environ Health; 2005 Feb; 4(1):2. PubMed ID: 15701170
[TBL] [Abstract][Full Text] [Related]
25. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
27. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
28. Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid activity in the female rat. A focus on the EDSTAC recommendations.
Goldman JM; Laws SC; Balchak SK; Cooper RL; Kavlock RJ
Crit Rev Toxicol; 2000 Mar; 30(2):135-96. PubMed ID: 10759430
[TBL] [Abstract][Full Text] [Related]
29. Small fish models for identifying and assessing the effects of endocrine-disrupting chemicals.
Ankley GT; Johnson RD
ILAR J; 2004; 45(4):469-83. PubMed ID: 15454686
[TBL] [Abstract][Full Text] [Related]
30. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
31. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
32. Are all EDC effects mediated via steroid hormone receptors?
Fisher JS
Toxicology; 2004 Dec; 205(1-2):33-41. PubMed ID: 15458788
[TBL] [Abstract][Full Text] [Related]
33. The U.S. federal framework for research on endocrine disruptors and an analysis of research programs supported during fiscal year 1996.
Reiter LW; DeRosa C; Kavlock RJ; Lucier G; Mac MJ; Melillo J; Melnick RL; Sinks T; Walton BT
Environ Health Perspect; 1998 Mar; 106(3):105-13. PubMed ID: 9443998
[TBL] [Abstract][Full Text] [Related]
34. Endocrine disrupting chemicals research program of the U.S. Environmental Protection Agency: summary of a peer-review report.
Harding AK; Daston GP; Boyd GR; Lucier GW; Safe SH; Stewart J; Tillitt DE; Van Der Kraak G
Environ Health Perspect; 2006 Aug; 114(8):1276-82. PubMed ID: 16882539
[TBL] [Abstract][Full Text] [Related]
35. Toxicity testing and endocrine disrupting chemicals.
Vandenberg LN
Adv Pharmacol; 2021; 92():35-71. PubMed ID: 34452691
[TBL] [Abstract][Full Text] [Related]
36. Economic benefits of using adaptive predictive models of reproductive toxicity in the context of a tiered testing program.
Martin MT; Knudsen TB; Judson RS; Kavlock RJ; Dix DJ
Syst Biol Reprod Med; 2012 Feb; 58(1):3-9. PubMed ID: 22239076
[TBL] [Abstract][Full Text] [Related]
37. A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids.
Kolle SN; Ramirez T; Kamp HG; Buesen R; Flick B; Strauss V; van Ravenzwaay B
Regul Toxicol Pharmacol; 2012 Jul; 63(2):259-78. PubMed ID: 22554500
[TBL] [Abstract][Full Text] [Related]
38. Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors.
Keane KA; Parker GA; Regan KS; Picut C; Dixon D; Creasy D; Giri D; Hukkanen RR
Toxicol Pathol; 2015 Dec; 43(8):1047-63. PubMed ID: 25948506
[TBL] [Abstract][Full Text] [Related]
39. The US Federal Tox21 Program: A strategic and operational plan for continued leadership.
Thomas RS; Paules RS; Simeonov A; Fitzpatrick SC; Crofton KM; Casey WM; Mendrick DL
ALTEX; 2018; 35(2):163-168. PubMed ID: 29529324
[TBL] [Abstract][Full Text] [Related]
40. Analysis of EPA's endocrine screening battery and recommendations for further review.
Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
